GLP-1 Agonists in Type 1 Diabetes Mellitus

Annals of Pharmacotherapy

Volumn 50, Issue 8, 2016, Pages 656-665

  Janzen, Kristin M ^a,b   Steuber, Taylor D ^a,b   Nisly, Sarah A ^a,b  

^a BUTLER UNIVERSITY   (United States)

^b INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

albiglutide; diabetes; dulaglutide; exenatide; GLP 1 agonists; liraglutide; type 1 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PRAMLINTIDE; ANTIDIABETIC AGENT; DULAGLUTIDE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INCRETIN; PEPTIDE; RGLP-1 PROTEIN; VENOM;

GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFORMATION RETRIEVAL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONOTHERAPY; OBESITY; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INCRETINS; LIRAGLUTIDE; PEPTIDES; RECOMBINANT FUSION PROTEINS; VENOMS;

EID: 84978540604     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016651279     Document Type: Review

References (44)

1. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. http://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html. Accessed January 5, 2016.
2. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up [published online February9, 2016]. Diabetes Care. doi:10.2337/dc15-1990.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. B.ConwayR.MillerT.Costacou. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398-404.
5. E.KielgastJ.HolstS.Madsbad. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes. 2011;60:1599-1607.
6. J.PettusI.HirschS.Edelman. GLP-1 agonists in type 1 diabetes. Clin Immunol. 2013;149:317-323.
7. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2016;39(suppl 1):S13-S22.
8. L.HarrisonP.MoraG.ClarkI.Lingvay. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med. 2013;61:40-44.
9. D.Nathan. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16.
10. R.E.RatnerR.DickeyM.Fineman. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212.
11. R.MoonL.BascombeR.Holt. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition, and patient well-being. Diabetes Obes Metab. 2007;9:143-145.
12. B.NwosuL.MarandaK.Cullen. A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One. 2015;10:e1-e16.
13. S.L.EllisE.G.MoserJ.K.Snell-Bergeon. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28:1176-1181.
14. B.A.PerkinsD.Z.I.CherneyN.Soleymanlou. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One. 2015;10:e0141085.
15. M.DeGeeterB.Williamson. Alternative agents in type 1 diabetes patients in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors. J Pharm Pract. 2016;29:144-159.
16. K.Hari KumarA.ShaikhP.Prusty. Addition of exenatide or sitaliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100:e55-e58.
17. V.S.RamanK.J.MasonL.M.Rodriguez. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33:1294-1296.
18. I.CrisciM.AragonaK.S.PolitiG.DanieleS.Del Prato. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol. 2015;52:1129-1133.
19. S.Delgado-ArosD.KimD.Burton. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424-G431.
20. K.RotherL.SpainWesley. Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32:2251-2257.
21. V.S.RenukuntlaN.RamchandaniJ.TrastM.CantwellR.Heptulla. Role of glucagon like peptide 1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol. 2014;8:1011-1017.
22. T.GhaziL.RinkJ.Sherr. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 2014;37:210-216.
23. A.N.TrainaM.E.LullA.C.Hui. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014;38:269-272.
24. G.SarkarM.AlattarR.J.Brown. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014;37:660-670.
25. Yale University. A phase II trial to examine the effect of subcutaneous exenatide (Bydureon®) on glucose control in patients with type I diabetes. http://www.clinicaltrials.gov/ct2/show/NCT01928329. Accessed February 28, 2016.
26. T.DejgaardC.FrandsenT.Hansen. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4:221-232.
27. C.S.FrandsenT.F.DejgaardJ.J.HolstH.U.AndersenB.ThorsteinssonS.Madsbad. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care. 2015;38:2250-2257.
28. U.KielgastJ.HolstT.KrarupS.Madsbad. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care. 2011;34:1463-1468.
29. A.VaranasiN.BelliniD.Rawak. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.
30. N.KuhadiyaR.MalikN.Bellini. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013;19:963-967.
31. Hvidovre University Hospital. The Lira Pump trial. http://www.clinicaltrials.gov/ct2/show/NCT02351232. Accessed February 28, 2016.
32. Exenatide. Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics; Updated January1, 2016; Accessed February 28, 2016.
33. Liraglutide. Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics; Updated December16, 2015; Accessed February 28, 2016.
34. ® [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2015.
35. ® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2015.
36. X.GuoQ.YangJ.Dong. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic reviewClin Drug Investig. 2016; 36:433–441.
37. R.W.ThomsenL.PedersenN.MøllerJ.KahlertH.Beck-NielsenH.T.Sørensen. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care. 2015;38:1089-1098.
38. T.WangF.WangZ.Gou. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015;17:32-41.
39. F.SunS.WuS.Guo. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26-37.
40. O.E.JohansenR.Whitfield. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol. 2008;66:568-569.
41. W.J.WeiseM.S.SivanandyC.A.BlockR.J.Comi. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32:e22-e23.
42. M.DaviesC.BainS.Atkin. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39:222-230.
43. T.IdornF.KnopM.Jorgensen. Safety and efficacy of liraglutide in patients with type 2 diabetes and end stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care. 2016;39:206-213.
44. GlaxoSmithKline. Albiglutide versus placebo in insulin-treated subjects with new-onset type 1 diabetes mellitus. https://www.clinicaltrials.gov/ct2/show/NCT02284009. Accessed February 28, 2016.